FM4 148
CONTENTS
e u r o p e a n u r o l o g y , vo l . 7 3 , n o . 1 , J a nu a ry 2 0 1 8
e1
The
Platinum
Hall of Fame
http://dx.doi.org/10.1016/j.eururo.2017.10.0241
New Insights into Adjuvant Renal Cell Carcinoma Treatment with Vascular Endothelial Growth Factor Inhibitors: What Have We Learned So Far?B. Escudier, M. Staehler
Adjuvant treatment of renal cell carcinoma with vascular endothelial growth factor
inhibitors is feasible and effective with careful patient selection and standard dosing
levels.
4
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)H. Borgmann, N. Lallous, D. Ozistanbullu, E. Beraldi, N. Paul, K. Dalal, L. Fazli, A. Haferkamp,
P. Lejeune, A. Cherkasov, M.E. Gleave
Our results provide a rationale for further clinical evaluation of darolutamide
in enzalutamide-resistant castration-resistant prostate cancer. In an evolving
treatment landscape of castration-resistant prostate cancer, darolutamide might
play a role, in particular in combination with circulating tumor DNA assays,
in a precision urologic oncology setting.
9
Innovative Therapies to Overcome Resistance to Enzalutamide: Perspective on the Use of DarolutamideZ. Culig
11
Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative ReviewC.J.D. Wallis, A. Glaser, J.C. Hu, H. Huland, N. Lawrentschuk, D. Moon, D.G. Murphy, P.L. Nguyen,
M.J. Resnick, R.K. Nam
Evaluation of treatment options for localized prostate cancer remains among
the highest priorities for comparative effectiveness research. Data to inform
comparisons of survival between surgery and radiotherapy have significant
limitations. Complications are common regardless of the treatment approach.
21
Randomised Controlled Trials Remain the Key to Progress in Localised Prostate CancerA. Tree, D. Dearnaley
23
Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS)R. Faria, M.O. Soares, E. Spackman, H.U. Ahmed, L.C. Brown, R. Kaplan, M. Emberton,
M.J. Sculpher
The use of multiparametric magnetic resonance imaging before transrectal
ultrasound-guided biopsy can detect more clinically significant prostate cancer
and be cost effective compared with the use of imaging post-biopsy.
PlatinumOpinion
Platinum Priorities
Brief Correspondence,
Review Articles and
Original Articles together with
the Full Length Editorials
Brief
Correspondence
Prostate Cancer